article thumbnail

Lower Prescription Drug Prices – A Tri-Partisan Call Across America

Health Populi

A new poll jointly conducted by Politico and the Harvard Chan School of Public Health bolsters my read on the latter issue – prescription drug pricing, which has become a mass popular culture union. This is the tactic that most Americans say could lower prescription drug prices. Why should U.S.

article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy

Bill of Health

Food and Drug Administration (FDA) advisory committees, an analysis of the key patents covering drugs recently approved by the FDA, and an examination of high-risk cardiovascular devices approved by the FDA for use in children and adolescents. Improving the Use of FDA Advisory Committees. N Engl J Med.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vendor Notebook: new tools and acquisitions from OptumRx, ScionHealth, others

Healthcare IT News - Telehealth

OptumRx launched Price Edge, a tool that compares pricing for traditional generic drugs to ensure members get the lowest prescription drug prices. FDA is currently reviewing use of Selux's NGP Gram-Negative panel. Inspira Technologies said it received patent approval from the U.S.

article thumbnail

In 2023, the U.S. Will Still Be the #1 Prescription Drug Spender in the World, IQVIA Forecasts

Health Populi

IQVIA rightly calls out digital therapeutics (DTx) in this year’s report, noting the growth of mobile apps and digital tools submitted to the FDA for clearance or approvals. The first FDA cleared DTx was reSET from Pear Therapeutics, cleared in November 2018. Thus far, the FDA has been welcoming to these concepts.

article thumbnail

New CDC Opioid Guidelines: Too Little, Too Late for Chronic Pain Patients?

Kaiser Health News

“We had a massive opioid problem that needed to be rectified,” said Antonio Ciaccia, president of 3 Axis Advisors , a consulting firm that analyzes prescription drug pricing. “But the federal crackdowns and guidelines have created collateral damage: patients left high and dry.”

Doctors 96
article thumbnail

New CDC Opioid Guidelines: Too Little, Too Late for Chronic Pain Patients?

Kaiser Health News

“We had a massive opioid problem that needed to be rectified,” said Antonio Ciaccia, president of 3 Axis Advisors , a consulting firm that analyzes prescription drug pricing. “But the federal crackdowns and guidelines have created collateral damage: patients left high and dry.”

Doctors 52
article thumbnail

CVS + Aetna: Inflection Point in US Healthcare, Merger Approved Update

Health Populi

Eli Lilly is currently under investigation for working, under your tenure, with other drug companies to needlessly raise the price of insulin.” ” Second, the National Academy of Science published a well-researched report supporting government prescription drug price negotiation.